Skip to content

Mesa Laboratories

US · MLAB #3485 by market cap
127.93 -5.48 -4.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 4.01 Expensive vs history 82nd percentile
5-year average 2.85 · #24 of 32 in Scientific & Technical Instruments
P/E ratio 119.84 In line with history 59th percentile
5-year average -3.84 · forward 53.33 · #18 of 18 in Scientific & Technical Instruments
P/S ratio 3.11 In line with history 59th percentile
5-year average 3.62 · forward 3.03 · #11 of 32 in Scientific & Technical Instruments

Vs. peers Scientific & Technical Instruments

Company Market cap P/E (TTM) P/B Div yield
Mesa Laboratories (MLAB) 719.03M 110.28 3.70 0.50%
Garmin (GRMN) 51.65B 25.75 5.41 1.46%
Keysight Technologies (KEYS) 44.43B 29.89 6.39 0.00%
Coherent (COHR) 36.87B 38.76 3.25 0.00%
Teledyne Technologies (TDY) 27.56B 27.41 2.47 0.00%
Fortive (FTV) 19.10B 30.85 3.21 0.39%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value117.63 Economic moatNone UncertaintyHigh

Trading 8.1% above Morningstar's fair value estimate.

Fair value

Mesa Laboratories Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 18% premium over our quantitative fair value estimate of $117.63 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The company's valuation metrics weaken our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 26.3% falls in the bottom 30% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are overvalued.

The company's liquidity is an additional cause for concern. Low liquidity can inhibit a company from meeting short-term obligations, potentially reducing financial stability and increasing distress risk. The firm's median trading volume over the past 60 days, a core component of liquidity, lies in the bottom 45% compared with global peers. Relatively low trading volume for these shares could lead to prices that don't accurately reflect the intrinsic value of shares. This characteristic further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Mesa Laboratories discussion 0 comments

Add a comment